Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blockernews2025-12-30T15:17:17+00:00December 30th, 2025|Endpoints News|
Federal judge blocks 340B drug pricing pilot ahead of Jan. 1 effective datenews2025-12-29T21:20:03+00:00December 29th, 2025|Endpoints News|
ASK Pharm makes China rights deal; Unicycive resubmits kidney drug after CRLnews2025-12-29T17:42:33+00:00December 29th, 2025|Endpoints News|
Nido Bio to wind down after underwhelming Phase 2 datanews2025-12-29T17:23:00+00:00December 29th, 2025|Endpoints News|
As gene editing tools multiply, the hunt for the final technology continuesnews2025-12-29T17:02:50+00:00December 29th, 2025|Endpoints News|
Ultragenyx, Mereo crash on late-stage bone disease failurenews2025-12-29T15:37:52+00:00December 29th, 2025|Endpoints News|
Genmab terminates Phase 3 lung cancer asset that BioNTech ditchednews2025-12-29T15:17:58+00:00December 29th, 2025|Endpoints News|
CMS unveils Medicare coverage model for weight loss drugsnews2025-12-26T18:31:31+00:00December 26th, 2025|Endpoints News|
Biohaven’s ion channel drug fails again, this time in major depressive disordernews2025-12-26T16:12:39+00:00December 26th, 2025|Endpoints News|
J&J axes eczema drug from $1.25B acquisitionnews2025-12-26T15:41:06+00:00December 26th, 2025|Endpoints News|
